Petros Pharmaceuticals, Inc. Selling, General and Administrative Expense
Petros Pharmaceuticals, Inc. (PTPI) reported Selling, General and Administrative Expense of $988.50 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-13
- Petros Pharmaceuticals, Inc. selling, general and administrative expense for the quarter ending 2026-06-30 was $988.50K, a 45.11% decline year-over-year.
- Petros Pharmaceuticals, Inc. selling, general and administrative expense for the quarter ending 2026-03-31 was $1.03M, a 29.57% decline year-over-year.
- Petros Pharmaceuticals, Inc. selling, general and administrative expense for the quarter ending 2025-12-31 was $391.49K, a 32.22% decline year-over-year.
- Petros Pharmaceuticals, Inc. selling, general and administrative expense for the quarter ending 2025-09-30 was $990.74K, a 17.26% decline year-over-year.
- Petros Pharmaceuticals, Inc. selling, general and administrative expense for fiscal 2025 was $4.64M, a 0.31% increase from fiscal 2024.
- Petros Pharmaceuticals, Inc. selling, general and administrative expense for fiscal 2024 was $4.63M, a 50.04% decline from fiscal 2023.
- Petros Pharmaceuticals, Inc. selling, general and administrative expense for fiscal 2023 was $9.26M, a 24.14% decline from fiscal 2022.
- Petros Pharmaceuticals, Inc. selling, general and administrative expense for fiscal 2022 was $12.21M, a 21.70% decline from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 3 month as first filed | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 6 month as first filed | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 9 month as first filed | Selling, General and Administrative Expense 12 month | Selling, General and Administrative Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $988.50K 10-Q · filed 2026-08-13 | $2.02M 10-Q · filed 2026-08-13 | $2.41M derived: sum of 3 quarters · filed 2026-08-13 | $3.40M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | $1.03M 10-Q · filed 2026-05-13 | $1.42M derived: sum of 2 quarters · filed 2026-05-13 | $2.41M derived: sum of 3 quarters · filed 2026-05-13 | $4.21M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | $391.49K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | $1.38M derived: sum of 2 quarters · filed 2026-04-15 | $3.18M derived: sum of 3 quarters · filed 2026-08-13 | $4.64M 10-K · filed 2026-04-15 | ||||
| 2025-09-30 | $990.74K 10-Q · filed 2025-11-13 | $2.79M derived: sum of 2 quarters · filed 2026-08-13 | $4.25M 10-Q · filed 2025-11-13 | $4.83M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | $1.80M 10-Q · filed 2026-08-13 | $3.26M 10-Q · filed 2026-08-13 | $3.84M derived: sum of 3 quarters · filed 2026-08-13 | $5.03M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | $1.46M 10-Q · filed 2026-05-13 | $2.04M derived: sum of 2 quarters · filed 2026-05-13 | $3.23M derived: sum of 3 quarters · filed 2026-05-13 | $4.58M derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2024-12-31 | $577.55K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | $1.77M derived: sum of 2 quarters · filed 2026-04-15 | $3.12M derived: sum of 3 quarters · filed 2026-04-15 | $4.63M 10-K · filed 2026-04-15 | $8.75M 10-K · filed 2025-03-31 | |||
| 2024-09-30 | $1.20M 10-Q · filed 2025-11-13 | $2.30M 10-Q · filed 2024-11-13 | $2.55M derived: sum of 2 quarters · filed 2025-11-13 | $4.05M 10-Q · filed 2025-11-13 | $7.30M 10-Q · filed 2024-11-13 | $6.93M derived: sum of 4 quarters · filed 2025-11-13 | ||
| 2024-06-30 | $1.35M 10-Q · filed 2025-08-14 | $2.29M 10-Q · filed 2024-08-14 | $2.85M 10-Q · filed 2025-08-14 | $5.00M 10-Q · filed 2024-08-14 | $5.73M derived: sum of 3 quarters · filed 2025-08-14 | $7.73M derived: sum of 4 quarters · filed 2025-08-14 | ||
| 2024-03-31 | $1.50M 10-Q · filed 2025-05-15 | $2.71M 10-Q · filed 2024-05-15 | $4.38M derived: sum of 2 quarters · filed 2025-05-15 | $6.38M derived: sum of 3 quarters · filed 2025-05-15 | $8.63M derived: sum of 4 quarters · filed 2025-05-15 | |||
| 2023-12-31 | $2.88M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $4.88M derived: sum of 2 quarters · filed 2025-03-31 | $7.13M derived: sum of 3 quarters · filed 2025-03-31 | $9.26M 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | $2.00M 10-Q · filed 2024-11-13 | $4.25M derived: sum of 2 quarters · filed 2024-11-13 | $6.38M 10-Q · filed 2024-11-13 | $9.31M derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | $2.25M 10-Q · filed 2024-08-14 | $4.38M 10-Q · filed 2024-08-14 | $7.30M derived: sum of 3 quarters · filed 2024-08-14 | $9.48M derived: sum of 4 quarters · filed 2024-08-14 | ||||
| 2023-03-31 | $2.13M 10-Q · filed 2024-05-15 | $5.05M derived: sum of 2 quarters · filed 2024-05-15 | $7.23M derived: sum of 3 quarters · filed 2024-05-15 | $10.44M derived: sum of 4 quarters · filed 2024-05-15 | ||||
| 2022-12-31 | $2.92M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $5.09M derived: sum of 2 quarters · filed 2024-04-01 | $8.31M derived: sum of 3 quarters · filed 2024-04-01 | $12.21M 10-K · filed 2024-04-01 | ||||
| 2022-09-30 | $2.17M 10-Q · filed 2023-11-15 | $5.39M derived: sum of 2 quarters · filed 2023-11-15 | $9.29M 10-Q · filed 2023-11-15 | $13.47M derived: sum of 4 quarters · filed 2023-11-15 | ||||
| 2022-06-30 | $3.22M 10-Q · filed 2023-08-14 | $7.11M 10-Q · filed 2023-08-14 | $11.30M derived: sum of 3 quarters · filed 2023-08-14 | $14.71M derived: sum of 4 quarters · filed 2023-08-14 | ||||
| 2022-03-31 | $3.90M 10-Q · filed 2023-05-15 | $8.08M derived: sum of 2 quarters · filed 2023-05-15 | $11.49M derived: sum of 3 quarters · filed 2023-05-15 | $15.61M derived: sum of 4 quarters · filed 2023-05-15 | ||||
| 2021-12-31 | $4.18M derived: 10-K 12 month − 10-Q/A 9 month · filed 2023-03-31 | $7.60M derived: sum of 2 quarters · filed 2023-03-31 | $11.71M derived: sum of 3 quarters · filed 2023-03-31 | $15.59M 10-K · filed 2023-03-31 | ||||
| 2021-09-30 | $3.41M 10-Q/A · filed 2022-11-15 | $7.53M derived: sum of 2 quarters · filed 2022-11-15 | $11.41M 10-Q/A · filed 2022-11-15 | $15.09M derived: sum of 4 quarters · filed 2022-11-15 | ||||
| 2021-06-30 | $4.12M 10-Q · filed 2022-08-12 | $8.00M 10-Q · filed 2022-08-12 | $11.68M derived: sum of 3 quarters · filed 2022-08-12 | $14.80M derived: sum of 4 quarters · filed 2022-08-12 | ||||
| 2021-03-31 | $3.88M 10-Q · filed 2022-05-16 | $7.56M derived: sum of 2 quarters · filed 2022-05-16 | $10.68M derived: sum of 3 quarters · filed 2022-05-16 | $14.74M derived: sum of 4 quarters · filed 2022-05-16 | ||||
| 2020-12-31 | $3.68M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $6.80M derived: sum of 2 quarters · filed 2022-03-31 | $10.86M derived: sum of 3 quarters · filed 2022-03-31 | $15.67M 10-K · filed 2022-03-31 | ||||
| 2020-09-30 | $3.12M 10-Q · filed 2021-11-15 | $7.18M derived: sum of 2 quarters · filed 2021-11-15 | $12.00M 10-Q · filed 2021-11-15 | |||||
| 2020-06-30 | $4.06M 10-Q · filed 2021-08-16 | $8.88M 10-Q · filed 2021-08-16 | ||||||
| 2020-03-31 | $4.82M 10-Q · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B |